堃博醫療-B(2216.HK)大漲30% 與怡亞通達成戰略合作提高產品貯運安全性及響應速度
格隆匯11月9日丨堃博醫療近日漲幅不斷擴大,今日盤中一度漲30%報2.33港元,為連續第4日上漲,股價創9月21日以來新高。堃博醫療是介入呼吸病學領域的開拓者,在中國和全球範圍內提供創新型肺部疾病解決方案,已建立由18種產品組成的強大呼吸介入診療管線,多款產品在中國已經實現商業化,覆蓋全國多個省份。11月6日,2022上海進博會期間,堃博醫療與中國供應鏈服務龍頭企業怡亞通達成戰略合作伙伴關係,充分發揮雙方的核心優勢,以合作平台整合資源,優勢互補,提高競爭力,怡亞通將以專業供應鏈服務助力堃博醫療的肺部介入診療產品覆蓋更廣闊的市場。本次合作是一次高端創新醫療器械與數字化產業鏈供應鏈的強強聯合,將大大提高堃博醫療產品貯運安全性及響應速度。堃博醫療與怡亞通在全國的合作正在穩步推進中,通過戰略合作推動醫療器械物流的高效集成管控與優化。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.